<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99227">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02014558</url>
  </required_header>
  <id_info>
    <org_study_id>2215-CL-0101</org_study_id>
    <nct_id>NCT02014558</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety and tolerability, including the maximum
      tolerated dose, of ASP2215 in subjects with relapsed or treatment-refractory acute myeloid
      leukemia (AML).  This study will also determine the pharmacokinetic (PK) parameters of
      ASP2215.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and Tolerability assessed through adverse events to determine maximum tolerated dose</measure>
    <time_frame>up to 18 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP2215:  AUC24</measure>
    <time_frame>Day -2 pre-dose and up to Day 22 in Cycle 1 and pre-dose on Day 1 of each cycle subsequent 28 day cycle for an expected average of 4 cycles</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration time curve at 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP2215:  Cmax</measure>
    <time_frame>Day -2 pre-dose and up to Day 22 in Cycle 1 and pre-dose on Day 1 of each cycle subsequent 28 day cycle for an expected average of 4 cycles</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum  Concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP2215:  Ctrough</measure>
    <time_frame>Day -2 pre-dose and up to Day 22 in Cycle 1 and pre-dose on Day 1 of each cycle subsequent 28 day cycle for an expected average of 4 cycles</time_frame>
    <safety_issue>No</safety_issue>
    <description>Minimum Concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP2215:  tmax</measure>
    <time_frame>Day -2 pre-dose and up to Day 22 in Cycle 1 and pre-dose on Day 1 of each cycle subsequent 28 day cycle for an expected average of 4 cycles</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to attain Cmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>up to 18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>Up to 18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia free survival</measure>
    <time_frame>up to 18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ASP2215 in co-administration with strong or moderate CYP3A4 (Cytochrome P450-isozyme3A4) inhibitors: AUC24</measure>
    <time_frame>Pre-dose, Day 1, Cycle 1 and up to Cycle 2, Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration time curve at 24 hours for ASP2215 as single agent and when combined with CYP3A4 inhibitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ASP2215 in co-administration with strong or moderate CYP3A4 (Cytochrome P450-isozyme3A4) inhibitors: Cmax</measure>
    <time_frame>Pre-dose, Day 1, Cycle 1 and up to Cycle 2, Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum Concentration for ASP2215 as single agent and when combined with CYP3A4 inhibitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ASP2215 in co-administration with strong or moderate CYP3A4 (Cytochrome P450-isozyme3A4) inhibitors: Ctrough</measure>
    <time_frame>Pre-dose, Day 1, Cycle 1 and up to Cycle 2, Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Minimum Concentration for ASP2215 as single agent and when combined with CYP3A4 inhibitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ASP2215 in co-administration with strong or moderate CYP3A4 (Cytochrome P450-isozyme3A4) inhibitors: tmax</measure>
    <time_frame>Pre-dose, Day 1, Cycle 1 and up to Cycle 2, Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to attain Cmax for ASP2215 as single agent and when combined with CYP3A4 inhibitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of midazolam in co-administration with ASP2215: AUC24</measure>
    <time_frame>Pre-dose and up to Day 15 in Cycle 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration time curve at 24 hours for midazolam as single agent and when combined with ASP2215</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of midazolam in co-administration with ASP2215: Cmax</measure>
    <time_frame>Pre-dose and up to Day 15 in Cycle 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum Concentration for midazolam as single agent and when combined with ASP2215</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of midazolam in co-administration with ASP2215: Ctrough</measure>
    <time_frame>Pre-dose and up to Day 15 in Cycle 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Minimum Concentration for midazolam as single agent and when combined with ASP2215</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of midazolam in co-administration with ASP2215: tmax</measure>
    <time_frame>Pre-dose and up to Day 15 in Cycle 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to attain Cmax for midazolam as single agent and when combined with ASP2215</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">145</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP2215</intervention_name>
    <description>tablet</description>
    <arm_group_label>Dose Escalation Cohort</arm_group_label>
    <arm_group_label>Dose Expansion Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is defined as morphologically documented primary or secondary AML by the
             World Health Organization (WHO) criteria (2008) and fulfills one of the following:

               -  Refractory to at least 1 cycle of induction chemotherapy

               -  Relapsed after achieving remission with a prior therapy

          -  Subject has an Eastern Cooperative Oncology Group (ECOG) performance status &lt;= 2.

          -  Subject's interval from prior treatment to time of study drug administration is at
             least 2 weeks for cytotoxic agents (except hydroxyurea given for controlling blast
             cells), or at least 5 half-lives for prior experimental agents or noncytotoxic
             agents, including immunosuppressive therapy post hematopoietic stem cell
             transplantation (HSCT).

        Exclusion Criteria:

          -  Subject was diagnosed as acute promyelocytic leukemia (APL).

          -  Subject has BCL-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).

          -  Subject has active malignant tumors other than AML or Myelodysplastic syndrome (MDS).

          -  Subject has persistent nonhematological toxicities of  &gt;=  Grade 2 (Common
             Terminology Criteria for Adverse Events v4), with symptoms and objective findings,
             from prior AML treatment (including chemotherapy, kinase inhibitors, immunotherapy,
             experimental agents, radiation, or surgery).

          -  Subject has had hematopoietic stem cell transplant (HSCT) and meets any of the
             following:

               -  Is within 2 months of transplant from C1D1

               -  Has clinically significant graft-versus-host disease requiring treatment

               -  Has &gt;= Grade 2 persistent non-hematological toxicity related to the transplant
                  Donor lymphocytes infusion (DLI) is not permitted &lt;= 30 days prior to study
                  registration or during the first cycle of treatment on the study in Cohort 1 and
                  first two cycles of the treatment in Cohort 2

          -  Subject has clinically active central nervous system leukemia

          -  Subject has disseminated intravascular coagulation abnormality (DIC)

          -  Subject has had major surgery within 4 weeks prior to the first study dose.

          -  Subject has had radiation therapy within 4 weeks prior to the first study dose

          -  Subject has congestive heart failure New York Heart Association (NYHA) class 3 or 4,
             or subject with a history of congestive heart failure NYHA class 3 or 4 in the past,
             unless a screening echocardiogram performed within 3 months prior to study entry
             results in a left ventricular ejection fraction that is â‰¥ 45%

          -  Subject requires treatment with concomitant drugs that are strong inhibitors or
             inducers of Cytochrome P450-isozyme3A4 (CYP3A4) with the exception of antibiotics,
             antifungals, and antivirals that are used as standard of care post-transplant or to
             prevent or treat infections and other such drugs that are considered absolutely
             essential for the care of the subject

          -  Subject required treatment with concomitant drugs that target serotonin 5HT1R or
             5HT2BR receptors or sigma nonspecific receptor with the exception of drugs that are
             considered absolutely essential for the care of the subject.

          -  Subject has an active uncontrolled infection

          -  Subject is known to have human immunodeficiency virus infection

          -  Subject has active hepatitis B or C, or other active hepatic disorder
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Executive Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Astellas Pharma Global Development</last_name>
    <phone>800-888-7704</phone>
    <phone_ext>5473</phone_ext>
    <email>clintrials.info@us.astellas.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1678</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania-Abramson CCC-Dept.of Hem Onc</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Ctr</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>November 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>ASP2215</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
